GE HealthCare Technologies (GEHC) is back in focus after unveiling the LOGIQ e laptop ultrasound family, along with its new Invenia ABUS Prime and ABUS StreamVue systems, all recently cleared by U.S. and European regulators.

GE HealthCare Technologies has seen short term momentum pick up, with a 1 month share price return of 10.96% and a 3 month share price return of 13.08%. However, the year to date share price return is down 13.34% and the 1 year total shareholder return is broadly flat at 0.13%.

If you are interested in how other health related technology stocks are trading around similar product launches, it could be a good time to scan the market using the 42 healthcare AI stocks

Is GE HealthCare Technologies now a growth story supported by recent ultrasound launches, steady revenue of US$21.27b, and net income of US$1.99b, or do the PCS challenges and share price pullback indicate a potential valuation trap?

Most Popular Narrative: 12.2% Undervalued

Against GE HealthCare Technologies' last close of $71.77, the most followed valuation narrative places fair value higher at $81.72, built on detailed revenue and earnings assumptions.

The analysts have a consensus price target of $81.72 for GE HealthCare Technologies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $96.0, and the most bearish reporting a price target of just $67.0.

Want to see what sits under that spread in outcomes? The narrative leans on measured revenue growth, firmer margins and a future earnings multiple below many peers. The real story is in how those three levers combine over time.

Result: Fair Value of $81.72 (UNDERVALUED)

However, GE HealthCare Technologies still faces tariff pressure and ongoing PCS execution questions. These factors could challenge margin assumptions and weaken confidence in the current undervalued narrative.

Next Steps

Given the mix of optimism and caution around GE HealthCare Technologies, it may be useful to review the data yourself and quickly form your own view with the help of the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond GE HealthCare Technologies?

If you are serious about building a stronger portfolio, do not stop with GE HealthCare Technologies. Use the Simply Wall Street Screener to quickly surface fresh opportunities across different styles and risk profiles.

• Target resilient returns by focusing on companies with dependable payouts and financial strength through the 8 dividend fortresses.
• Spot potential mispricings before the crowd by scanning for quality companies trading below their implied worth using the 49 high quality undervalued stocks.
• Prioritise stability and sleep a little easier by filtering for companies that pass strict balance sheet and fundamentals checks with the solid balance sheet and fundamentals stocks screener (49 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.